Journal of Biological Chemistry · 2004 · 75 citations · 46 references
Life SciencesCell BiologyMolecular BiologyMolecular NeuroscienceNeurodegenerationPrion DiseasesEndomembrane SystemNeuropathology Of Prion DiseasePrion Protein MisfoldingPrion Protein StructurePrion ReplicationNeurodegeneration PathogenesisPrion Disease PathologyPrion PathogenesisPrion Protein DepositionPrion Protein FoldingPrion Protein OligomerizationPrion Protein Stability
The conversion of the normal cellular prion protein (PrPC) into the abnormal scrapie isoform (PrPSc) is a key feature of prion diseases. The pathogenic mechanisms and the subcellular sites of the conversion are complex and not completely understood. In particular, little is known on the role of the early compartment of the secretory pathway in the processing of PrPC and in the pathogenesis of prion diseases. In order to interfere with the intracellular traffic of endogenous PrPC we have generated two anti-prion single chain antibody fragments (scFv) directed against different epitopes, each fragment tagged either with a secretory leader or with the ER retention signal KDEL. The stable expression of these constructs in PC12 cells allowed us to study their specific effects on the synthesis, maturation, and processing of endogenous PrPC and on PrPSc formation. We found that ER-targeted anti-prion scFvs retain PrPC in the ER and inhibit its translocation to the cell surface. Retention in the ER strongly affects the maturation and glycosylation state of PrPC, with the appearance of a new aberrant endo-H sensitive glycosylated species. Interestingly, ER-trapped PrPC acquires detergent insolubility and proteinase K resistance. Furthermore, we show that ER-targeted anti-prion antibodies prevent PrPSc accumulation in nerve growth factor-differentiated PC12 cells, providing a new tool to study the molecular pathology of prion diseases. The conversion of the normal cellular prion protein (PrPC) into the abnormal scrapie isoform (PrPSc) is a key feature of prion diseases. The pathogenic mechanisms and the subcellular sites of the conversion are complex and not completely understood. In particular, little is known on the role of the early compartment of the secretory pathway in the processing of PrPC and in the pathogenesis of prion diseases. In order to interfere with the intracellular traffic of endogenous PrPC we have generated two anti-prion single chain antibody fragments (scFv) directed against different epitopes, each fragment tagged either with a secretory leader or with the ER retention signal KDEL. The stable expression of these constructs in PC12 cells allowed us to study their specific effects on the synthesis, maturation, and processing of endogenous PrPC and on PrPSc formation. We found that ER-targeted anti-prion scFvs retain PrPC in the ER and inhibit its translocation to the cell surface. Retention in the ER strongly affects the maturation and glycosylation state of PrPC, with the appearance of a new aberrant endo-H sensitive glycosylated species. Interestingly, ER-trapped PrPC acquires detergent insolubility and proteinase K resistance. Furthermore, we show that ER-targeted anti-prion antibodies prevent PrPSc accumulation in nerve growth factor-differentiated PC12 cells, providing a new tool to study the molecular pathology of prion diseases. The normal cellular prion protein (PrPC) 1The abbreviations used are: PrPC, cellular isoform of prion protein; PrPSc, scrapie isoform of PrP; GPI, glycosylphosphatidylinositol; scFv, single-chain variable fragment; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; BSA, bovine serum albumin; NGF, nerve growth factor; PK, proteinase K; ER, endoplasmic reticulum; PNGase, peptide-N-glycosidase; Endo-H, endoglycosidase H; PI-PLC, phosphatidylinositol-specific phospholipase C; MTT, 3,(4,5-di-methylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide; BFA, brefeldin A; FBS, fetal bovine serum. 1The abbreviations used are: PrPC, cellular isoform of prion protein; PrPSc, scrapie isoform of PrP; GPI, glycosylphosphatidylinositol; scFv, single-chain variable fragment; ELISA, enzyme-linked immunosorbent assay; PBS, phosphate-buffered saline; BSA, bovine serum albumin; NGF, nerve growth factor; PK, proteinase K; ER, endoplasmic reticulum; PNGase, peptide-N-glycosidase; Endo-H, endoglycosidase H; PI-PLC, phosphatidylinositol-specific phospholipase C; MTT, 3,(4,5-di-methylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide; BFA, brefeldin A; FBS, fetal bovine serum. is a copper-binding sialoglycoprotein, present in a variety of tissues but mainly expressed in the central nervous system. The precise physiological function of PrPC remains enigmatic but a wealth of experimental data demonstrates its essential role in the susceptibility and in the pathogenesis of transmissible spongiform encephalopathies (TSEs) or prion diseases (1Prusiner S.B. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13363-13383Crossref PubMed Scopus (5052) Google Scholar, 2Goldfarb L.G. Brown P. Annu. Rev. Med. 1995; 46: 57-65Crossref PubMed Scopus (58) Google Scholar, 3Weissmann C. Raeber A.J. Montrasio F. Hegyi L. Klein M.A. Aguzzi A. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 2001; 356: 177-184Crossref PubMed Scopus (48) Google Scholar, 4Aguzzi A. Polymenidou M. Cell. 2004; 116: 313-327Abstract Full Text Full Text PDF PubMed Scopus (498) Google Scholar). During the biogenesis, PrPC is co-translationally directed into the secretory pathway to reach the cell surface. The maturation of PrPC is achieved by the attachment of two N-linked complex carbohydrate moieties, and the addition of a GPI anchor at its C terminus (1Prusiner S.B. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 13363-13383Crossref PubMed Scopus (5052) Google Scholar). All three forms of prion diseases, hereditary, sporadic, and acquired by infection, share the same pathogenic mechanism based on the conversion of the normal cellular prion protein, PrPC, into the pathogenic scrapie PrP isoform, PrPSc (5Cohen F.E. Pan K.M. Huang Z. Baldwin M. Fletterick R.J. Prusiner S.B. Science. 1994; 264: 530-531Crossref PubMed Scopus (438) Google Scholar). Spectroscopic studies reveal that approximately half of the α-helical structure of PrPC is converted to β-sheets structure in PrPSc. After conversion, the aggregated PrPSc becomes detergent-insoluble and partially resistant to proteolytic digestion (6Pan K.M. Baldwin M. Nguyen J. Gasset M. Serban A. Groth D. Mehlhorn I. Huang Z. Fletterick R.J. Cohen F.E. Prusiner S.B. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 10962-10966Crossref PubMed Scopus (2049) Google Scholar, 7Meyer R.K. McKinley M.P. Bowman K.A. Braunfeld M.B. Barry R.A. Prusiner S.B. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 2310-2314Crossref PubMed Scopus (513) Google Scholar). Proteolytic treatment of this form removes 60-70 residues from the N-terminal region of the protein, yielding a protease-resistant core called PrP27-30, whereas PrPC is completely digested (5Cohen F.E. Pan K.M. Huang Z. Baldwin M. Fletterick R.J. Prusiner S.B. Science. 1994; 264: 530-531Crossref PubMed Scopus (438) Google Scholar). Studies in cell culture have suggested that the conversion occurs post-translationally on the cell surface or in the endocytic pathway even though the precise subcellular sites and the molecular mechanisms of this process remain still poorly understood (8Caughey B. Raymond G.J. J. Biol. Chem. 1991; 266: 18217-18223Abstract Full Text PDF PubMed Google Scholar, 9Borchelt D.R. Taraboulos A. Prusiner S.B. J. Biol. Chem. 1992; 267: 16188-16199Abstract Full Text PDF PubMed Google Scholar, 10Caughey B. Br. Med. Bull. 2003; 66: 109-120Crossref PubMed Scopus (64) Google Scholar). In particular, little is known on the processing of prion protein in the endoplasmic reticulum and on the role of this compartment in the PrPC-PrPSc conversion. In cellular models of inherited prion disorders, misfolded mutant prion proteins accumulate in the ER, and activate the ER stress cytotoxic response, resulting in neuronal cell death (11Harris D.A. Br. Med. Bull. 2003; 66: 71-85Crossref PubMed Scopus (139) Google Scholar). Recent studies have also shown that a small percentage of nascent wild-type PrPC and at least two pathogenic mutants are subjected to retrograde transport from the ER, accumulation in the cytoplasm and degradation by the ubiquitin-proteasome system (12Ma J. Lindquist S. Proc. Natl. Acad. Sci. U. S. A. 2001; 98: 14955-14960Crossref PubMed Scopus (265) Google Scholar, 13Yedidia Y. Horonchik L. Tzaban S. Yanai A. Taraboulos A. EMBO J. 2001; 20: 5383-5391Crossref PubMed Scopus (221) Google Scholar, 14Zanusso G. Petersen R.B. Jin T. Jing Y. Kanoush R. Ferrari S. Gambetti P. Singh N. J. Biol. Chem. 1999; 274: 23396-23404Abstract Full Text Full Text PDF PubMed Scopus (150) Google Scholar, 15Jin T. Gu Y. Zanusso G. Sy M.S. Kumar A. Cohen M. Gambetti P. Singh N. J. Biol. Chem. 2000; 275: 38699-38704Abstract Full Text Full Text PDF PubMed Scopus (150) Google Scholar). Accumulation of PrPC in the cytoplasm might cause neurodegeneration, indicating a possible role of this degradation pathway in the pathogenesis of prion diseases (16Ma J. Wollmann R. Lindquist S. Science. 2002; 298: 1781-1785Crossref PubMed Scopus (426) Google Scholar). It has been reported that retrotransport of PrPC from trans-Golgi compartment toward the ER increases the production of PrPSc in persistently scrapie-infected neuroblastoma N2a cells F. A. B. S. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar). the protein from the ER by brefeldin of PrPSc, that ER compartment is not PrPSc A. Raeber A.J. D.R. Serban D. Prusiner S.B. Biol. Cell. 1992; PubMed Scopus Google Scholar). We the intracellular antibody to interfere with the intracellular of prion protein and to study the effects of PrPC on the PrPC-PrPSc conversion is based on the expression of antibodies and their to different intracellular S. M.S. A. EMBO J. PubMed Scopus Google Scholar, S. A. Biol. 1995; Full Text PDF PubMed Scopus Google Scholar, A. S. and Google Scholar). The its the cells in by the protein its to the S. P. N. A. 1994; PubMed Scopus Google Scholar, 1998; PubMed Scopus Google or by the to a different subcellular M. A. S. A. S. J. 2000; 267: PubMed Scopus Google Scholar). the ER retention have been used to in the ER, and inhibit their intracellular traffic the secretory pathway Proc. Natl. Acad. Sci. U. S. A. 1993; 90: PubMed Scopus Google Scholar, D. Cell. Biol. 1995; PubMed Google Scholar, M. R. D. M. S. S. 2003; PubMed Scopus Google Scholar). we the and the intracellular expression of two single chain antibody fragments (scFv) directed against different of the prion protein, to the secretory compartment of The anti-prion tagged with the ER retention signal used to the PrPC in the The stable expression of anti-prion scFvs in PC12 cells a surface of of PrPC to the ER also its maturation, its proteinase K and detergent we show that anti-prion prevent PrPSc in PC12 of the and of two anti-prion antibodies and a system A. S. J. A. J. A. J. PubMed Scopus Google Scholar). from of cell and the of a of and a of the of a of and a of used R. G. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). The and into the growth of D. A. 2000; PubMed Scopus Google Scholar). of in the in a P. A. L. Br. J. 1998; PubMed Scopus Google to prion protein and a by and anti-prion scFvs and the M. G. J. Biol. 1993; PubMed Scopus Google expressed in and by by the with of prion protein and of After with of scFv, in BSA, and the expression in cells, and fragments into the sites of the secretory and of the L. M. A. A. A. PubMed Scopus Google Scholar). of scFvs from the the and The scFv, from A. M. S. A. S. 1998; PubMed Scopus Google into the PrP expression in cells by A. of and in with fetal bovine serum and with with a of and PC12 cells in with serum and of stable cells with a of least of resistant neuronal PC12 cells on with in cells in or brefeldin A. I. S. S. 2004; PubMed Scopus Google Scholar). surface of PrPC, cells with and at with R. T. Pan T. M. Gambetti P. Sy M.S. J. Biol. 2000; PubMed Scopus Google in After with PBS, cells in at anti-prion and used antibodies and and used with with and prion cells with and in cell and and by at at The with of at After protein in and and at in the cells in and in in of proteins by in and to at with and and with and by and to cells in and in at with in serum and in and and the of the cells and cell subjected to with to of protein at proteins with and in and by with and to of and K at at to and detergent-insoluble in of After proteins from of cells in in the of and by at of proteins digested with different of and or by the addition of and cell in and proteins digested with in or in at digestion cells in proteins and of to the the of each PC12 cells in and with different of or brefeldin in M.B. J. PubMed Scopus Google Scholar). The data two in of PC12 cells with to by cells with and of scrapie at with from of from scrapie at of with and at in the of and in at and at digested with proteinase K at and at at PrPSc in of used the system to the of two and residues of and the at the C terminus of PrP G. D. Ferrari S. Hegyi I. Aguzzi A. S. S. R. Brown P. Petersen R.B. Gambetti P. Sy M.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: PubMed Scopus Google Scholar, R. C. Pan T. T. R. G. Sy M.S. J. 2003; PubMed Scopus Google Scholar). antibodies are PrPC and are to with PrPC and PrPSc R. T. Pan T. M. Gambetti P. Sy M.S. J. Biol. 2000; PubMed Scopus Google Scholar, G. D. Ferrari S. Hegyi I. Aguzzi A. S. S. R. Brown P. Petersen R.B. Gambetti P. Sy M.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: PubMed Scopus Google Scholar, T. M. R. T. Petersen R.B. S. Gambetti P. Sy M.S. J. Biol. Chem. 2001; Full Text Full Text PDF PubMed Scopus Google Scholar). and anti-prion scFvs expressed in and by and shown in the two fragments the same of the and of scFvs is shown in to the of and scFvs is ER-targeted PrPC in and fragments are to with PrPC in cells, we into intracellular expression in the secretory pathway of retention in the ER, the ER retention at the C terminus of the L. M. A. A. A. PubMed Scopus Google Scholar, S. F. M. P. A. 1995; PubMed Scopus (150) Google Scholar). We used to the anti-prion with PrPC in the or scFvs and PrPC into cells, and cells with anti-prion by and with to reveal the We found to the scFv, in from cells the and the scFvs and the the anti-prion and and the scFvs not with that the of PrPC, is by the is PrPC the of is not in this antibody fragment with PrP The is by of the The and the of PrPC by the same with the anti-prion The in by on the in and cells antibodies to fragments and and to reveal PrPC and are shown in and I. that anti-prion and the in the secretory and in the ER and we the of intracellular scFvs expression on PrPC we found that the expression of in a in the of PrPC in with the is in the the the expression of the fragment or the not the intracellular of PrPC and and with PrPC the of PrPC by the retention of PrPC in the ER by of the to the intracellular of the in the endoplasmic we the with the ER is shown in the precise with and of PrPC in cells, from a to the nerve growth by cell and into cells with and of Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar). PC12 cells PrPC on their cell and the not the of the endogenous PrPC R. D.A. J. 2000; PubMed Scopus Google Scholar). PC12 cells are to scrapie R. J. PubMed Scopus Google Scholar, R. J. PubMed Scopus Google Scholar). generated PC12 stable cell either or the is in PC12 cells, we and by the of fragments present in the of and shown in completely and not in the In of in the in and We used these two cell to the effects of the are by the specific retention of the PrPC in the PC12 cell also generated and used of endogenous PrPC in PC12 cells and cells is shown in PrPC surface in cells with PC12 cells PC12 cells and PrPC signal in small the In PrPC not in the of In these cells we a of ER PrPC not in cells not We the expression of the the state of PrPC in PC12 with is specific to PrPC residues of PC12 and cell three of PrPC the form at the forms of and the glycosylated forms of and In cells a of PrPC by of the and and a of the glycosylated species. in is Interestingly, the of the PrPC in cells not that retention of PrPC in the ER the of We used in with to the of N-linked to the of PrPC in PC12 and of the N-linked in the appearance of a of is the protein of PrPC, and a at N-terminal PrPC fragment is present in cell and also by the of N-linked glycosylation in with and of PrPC to the of the we that this PrPC is not PrPC, with either the leader at the terminus or the GPI anchor signal at the C but a partially glycosylated PrPC species. that the of PrPC not PC12 cells and the percentage of We the of PrPC in PC12 and with to the cell surface of PrPC is by in PC12 cells In of PrPC into the in cells In these cells, the of the PrPC is present the is not to the cell surface. of cell surface proteins the of PrPC the that to aberrant of the PrPC with the resulting in to that retention of PrPC in the ER of cells has a on and cellular of PrPC, resulting in a in the PrPC and the accumulation of The PrPC in to by is that and in the ER proteins with complex N-linked present in the are resistant to The expression of anti-prion fragments the PrPC in the these PrPC sensitive to endo-H this is the PC12 and PC12 cell with and with in PrPC endo-H digestion in PC12 cells and In endo-H treatment of cells a in the and glycosylated PrPC and the of the and that the is a core glycosylated PrPC has not the this we cells with BFA, a of the ER with and the of the proteins from these J. Cell. Full Text PDF PubMed Scopus Google Scholar). treatment of PC12 cells with different of and in a to that in cells in the PrPC accumulation of the and forms and appearance of the species. ER PrPC the and of PrPC biogenesis, we After of PrPC with and by In PC12 cells, three PrPC The the PrPC that processing PrPC increases and becomes the form in cells the complex glycosylated form or at the In in PC12 cells a to the PrPC with in is completely converted to complex of in PC12 cells the in cells the stable of It is that the form of PrPC in the the maturation of PrPC in PC12 cells is and on the the N-linked of PrPC in cells are not into complex and the PrPC maturation is the and transport of PrPC, we the PC12 cells and cells with The surface PrPC and the PrPC shown in of PrPC the cell surface and by treatment in PC12 cells a and and the in cells, of PrPC still of and Interestingly, the small of PrPC that the cell surface the not the this the cell surface degradation of the PrPC is also in in PC12 cells the PrPC to at this the PrPC still in cells indicating either a in the translocation process or in its we of PrPC in and found that the of PrPC in PC12 cells is in is in the of PrPC in cells is to of the PrPC in the ER and retention of PrPC in the ER of cells allowed us to the of maturation accumulation of misfolded PrPC in the ER at resulting in its PrPC in cell from cells or cells to a and a detergent-insoluble After by each with in PC12 cells the PrPC is in the In in cells, of PrPC is found in the detergent-insoluble We the of the PrPC from PC12 and cells by to treatment with different of at shown in PrPC from PC12 cells completely digested with of PrPC from cells resistant to PK, yielding three protease-resistant at and a of digestion of PrPC at treatment these we in cell the endoplasmic reticulum is the PrPC becomes detergent-insoluble and acquires resistance. The accumulation of and PrPC in PC12 cells not cellular and normal accumulation of misfolded proteins in the ER the cells to R.J. 1999; PubMed Scopus Google we specific ER stress are in In order to study the to with ER stress we the cells with different of brefeldin and and the cell by in the to these in wild-type PC12 and of PrPC PrPSc we the expression PrPSc accumulation in PC12 It has been shown that these cells scrapie from by R. J. PubMed Scopus Google Scholar, R. J. PubMed Scopus Google Scholar). we PC12 and cells with scrapie or infection, the of resistant PrPSc in cells or cells by with PrPC is in wild-type PC12 cells or cells and of resistant PrPSc in wild-type PC12 cells and cells and PrPSc the has not been PC12 and cells are to of PrPSc. In at PrPSc in wild-type PC12 cells but not in cells that cells are to PrPSc In to in cells scrapie is also are The the that anti-prion to the of the ER a and to inhibit the transport of PrPC to the cell surface. The of tool to interfere with the intracellular of PrPC proteins allowed to study the of PrPC and the role of the PrPC in the process of PrPSc formation. intracellular antibodies to function is their to with the endogenous in in the specific compartment are to S. A. Biol. 1995; Full Text PDF PubMed Scopus Google Scholar). studies and have the of this to interfere with proteins in the secretory of the and of single chain antibodies in this S. A. Biol. 1995; Full Text PDF PubMed Scopus Google Scholar, A. S. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar). anti-prion and in this are expressed in cells and in the Furthermore, is with the expression of these During its PrPC a of at the and C to the signal and the GPI anchor signal addition of N-linked of a and attachment of a GPI The anti-prion expression to the accumulation of PrPC in the ER and to the of this maturation We in particular, aberrant glycosylation of PrPC, with the appearance of a new species. aberrant PrPC is not or In the in treatment by either in or in The is of a in its from the is by of this is sensitive to endo-H a of that have not the protein from the ER by brefeldin in PC12 cells in a of PrPC the appearance of the we found a in the of PrPC The aberrant isoform stable of and is found in the the residues and of of the two sites glycosylation not the of to cellular G. D. Ferrari S. Hegyi I. Aguzzi A. S. S. R. Brown P. Petersen R.B. Gambetti P. Sy M.S. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: PubMed Scopus Google Scholar). We found a in PrPC glycosylation in PC12 cells the of the but not in cells the secretory of the same we that the processing of PrPC is by the of its from the ER to the of diseases have been to in the of secretory proteins M. 2002; PubMed Scopus Google Scholar). In the the aberrant protein and to reach its resulting in the of normal physiological proteins also form in the ER or in the known and R. R. EMBO 2001; Scopus Google Scholar). the to the and of cells R.J. 1999; PubMed Scopus Google Scholar). the the of secretory proteins also occurs in or in of glycosylation diseases, are by of the U. A. M.A. N. R.J. D. Cell. 1998; Full Text Full Text PDF PubMed Scopus Google and by in the glycosylation of proteins Cell. Sci. 2001; PubMed Scopus Google Scholar). We that PrPC in their the early pathway of the secretory partially resistant to and detergent-insoluble the are of in cell models of prion diseases (11Harris D.A. Br. Med. Bull. 2003; 66: 71-85Crossref PubMed Scopus (139) Google Scholar, S. D.A. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar, N. Zanusso G. S. Gambetti P. Petersen R.B. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google in PrPC are in their maturation, accumulate in the ER, to and B. C. L. R. D.A. J. Biol. Chem. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, Y. S. Y. Singh N. J. 2003; PubMed Scopus Google Scholar). In we that ER-trapped PrPC the same of inherited prion mutants but in the of the endoplasmic reticulum to a compartment the of detergent insolubility and of endogenous us to that accumulation of aberrant PrPC might from a in the ER of glycosylation in these have in the of forms of prion diseases in specific of PrPC are not cells accumulate misfolded PrPC in the ER, is on their or susceptibility to In with in cell models of prion diseases (11Harris D.A. Br. Med. Bull. 2003; 66: 71-85Crossref PubMed Scopus (139) Google this to the degradation system of PC12 in the ER are and degradation by the degradation studies have shown that this pathway is in the degradation of pathogenic PrPC the misfolded PrPC are and in system is not The of PrPC to PrPSc conversion is not completely understood. studies in cell models have the role of the cell studies suggested that conversion mainly occurs in the (8Caughey B. Raymond G.J. J. Biol. Chem. 1991; 266: 18217-18223Abstract Full Text PDF PubMed Google Scholar, 9Borchelt D.R. Taraboulos A. Prusiner S.B. J. Biol. Chem. 1992; 267: 16188-16199Abstract Full Text PDF PubMed Google Scholar, 10Caughey B. Br. Med. Bull. 2003; 66: 109-120Crossref PubMed Scopus (64) Google Scholar). We that in to PC12 cells, cells to scrapie not accumulate of PrPSc. that either the of PrPC-PrPSc conversion the PrPSc process have been The mechanism by PrPSc is not the of cell PrPSc at the of the is in cell the of cells to PrPSc is not to the of PrPSc present in the to cell It is possible that cells the of cell PrPC to the of PrPC-PrPSc conversion, shown by of PrPC reach the cell surface with a a specific of PrPC by intracellular antibodies the of PrPSc, and of surface proteins by a has been reported to prevent scrapie in and the of prion in S. M. R. C. D. J. EMBO J. 2001; 20: PubMed Scopus Google Scholar). intracellular the and PrPSc or PrPC interfere with the PrPC-PrPSc conversion In of but not also the of prion diseases in Sy M.S. R. R.J. R. B. T. 2003; PubMed Scopus Google Scholar). In the intracellular antibody a not the biogenesis, the cellular and the degradation of the prion protein but the to in the molecular in the pathogenesis of prion diseases, the of conversion and the cellular mechanisms the of PrPSc. these in studies the and specific anti-prion We S. A. the PrP and expression of PrP in cells, and D. providing nerve growth
46